DLL3 and neuroendocrine carcinoma: Expression of DLL3 was rare in non-neuroendocrine carcinomas (6/479, 1.3%) with two gastric adenocarcinomas showing a weak expression (2/69, 2.9%) and four positive pulmonary carcinomas—one weak (1.3%), three moderate (3.8%)—while a strong expression was never observed and all colorectal and pancreatic adenocarcinomas were entirely negative (Fig. 1J).